Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | TRIM24 | O15164 | 2/20 | 0.43 |
| ▸ | TRIM33 | Q9UPN9 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | ERN1 | O75460 | 2/20 | 0.35 |
| ▸ | HTR2C | P28335 | 2/20 | 0.35 |
| ▸ | SRC | P12931 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL548161 | 0.93 | LMNA (0.50) | LMNAKMT2AMEN1THRBBLM | |
| SCHEMBL547607 | 0.91 | LMNA (0.48) | LMNAKMT2AMEN1THRBBLM | |
| SCHEMBL31415807 | 0.91 | LMNA (0.48) | LMNAKMT2AMEN1THRBBLM | |
| SCHEMBL6764461 | 0.90 | MEN1 (0.43) | LMNAKMT2AMEN1THRBBLM | |
| SCHEMBL7792621 | 0.90 | LMNA (0.43) | LMNAKMT2AMEN1THRBBLM | |
| SCHEMBL12212996 | 0.90 | LMNA (0.43) | LMNAKMT2AMEN1THRBBLM | |
| SCHEMBL11675315 | 0.90 | MEN1 (0.46) | LMNAKMT2AMEN1THRBBLM | |
| SCHEMBL22284134 | 0.90 | MEN1 (0.46) | LMNAKMT2AMEN1THRBBLM | |
| SCHEMBL21647623 | 0.90 | MEN1 (0.46) | LMNAKMT2AMEN1THRBBLM | |
| SCHEMBL14236917 | 0.90 | MEN1 (0.46) | LMNAKMT2AMEN1THRBBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 284 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112194653-A | Pyrimidine benzimidazole heterozygote, preparation method and colon cancer resisting application | 宁夏厚泽生物医药科技有限公司 | 2021-01-08 | — | — | CN | claimed |
| US-4582903-A | Synthesis of unsaturated hydantoins with an inexpensive catalyst | STAUFFER CHEMICAL COMPANY (US) | 1986-04-15 | — | — | US | claimed |
| US-4345072-A | Process for the production of 5-arylidene hydantoins (B) | DEGUSSA AG (DE) | 1982-08-17 | — | — | US | claimed |
| US-20250304594-A1 | METHYL (R)-2-(FLUOROMETHYL)-5-OXO-4-PHENYL-4,5,6,7-TETRAHYDRO-1H-CYCLOPENTA[B]PYRIDINE-3-CARBOXYLATE AND METHYL (R)-2-(FLUOROMETHYL)-5-OXO-4-PHENYL-1,4,5,7-TETRAHYDROFURO[3,4-B]PYRIDINE-3-CARBOXYLATE AS Cav1,2 ACTIVATORS | NOVARTIS AG (CH) | 2025-10-02 | — | — | US | disclosed |
| US-12365690-B2 | Methyl (R)-2-(fluoromethyl)-5-oxo-4-phenyl-4,5,6,7-tetrahydro-1H-cyclopenta[B]pyridine-3-carboxylate and methyl 2-(fluoromethyl)-5-oxo-4-phenyl-1,4,5,7-tetrahydrofuro[3,4-b]pyrodine-3-carboxylate as Cav1.2 activators | NOVARTIS AG (CH) | 2025-07-22 | — | — | US | disclosed |
| EP-4545515-A1 | BCL-2 INHIBITORS | BeiGene Switzerland GmbH (CH) | 2025-04-30 | — | — | EP | disclosed |
| CN-115836076-B | Compounds as CAV1.2 activators | 诺华股份有限公司 | 2025-04-25 | — | — | CN | disclosed |
| US-20250002499-A1 | Methyl 2-(Fluoromethyl)-5-Oxo-4-Phenyl-4,5,6,7-Tetrahydro-1h-Cyclopenta[B]Pyridine-3-Carboxylate And Methyl 2- (Fluoromethyl0-5-Oxo-4-Phenyl-1,4,5,7-Tetrahydrofuro[3,4-B]Purodine-3-Carboxylate As Cav1.2 Activators | CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD (CN) | 2025-01-02 | — | — | US | disclosed |
| CN-112513737-B | Underlayer film forming composition | 三菱瓦斯化学株式会社 | 2024-11-15 | — | — | CN | disclosed |
| US-20240376104-A1 | Bcl-2 Inhibitors | BEIGENE LTD. (KY) | 2024-11-14 | — | — | US | disclosed |
| US-12077536-B2 | BCL-2 inhibitors | BEIGENE, LTD. (KY) | 2024-09-03 | — | — | US | disclosed |
| EP-0210683-A1 | Promotion of raney nickel catalyst | STAUFFER CHEMICAL COMPANY (US) | 1987-02-04 | — | — | EP | disclosed |
| US-4613691-A | Preparation of amino acids from unsaturated hydantoins | STAUFFER CHEMICAL COMPANY (US) | 1986-09-23 | — | — | US | disclosed |
| US-4582903-A | Synthesis of unsaturated hydantoins with an inexpensive catalyst | STAUFFER CHEMICAL COMPANY (US) | 1986-04-15 | — | — | US | disclosed |
| EP-0177072-A2 | Preparation of amino acids from unsaturated hydantoins | STAUFFER CHEMICAL COMPANY (US) | 1986-04-09 | — | — | EP | disclosed |
| US-4345072-A | Process for the production of 5-arylidene hydantoins (B) | DEGUSSA AG (DE) | 1982-08-17 | — | — | US | disclosed |
| EP-0009206-B1 | FLUOR-CONTAINING 1,4-DIHYDROPYRIDINES, PHARMACEUTICALS CONTAINING THEM AND PROCESS FOR THEIR PREPARATION | BAYER AG (DE) | 1981-10-14 | — | — | EP | disclosed |
| US-4256749-A | HYPOTENSIVE AGENTS, CIRCULATION | BAYER AKTIENGESELLSCHAFT (DE) | 1981-03-17 | — | — | US | disclosed |
| EP-0009206-A2 | Fluor-containing 1,4-dihydropyridines, pharmaceuticals containing them and process for their preparation | BAYER AG (DE) | 1980-04-02 | — | — | EP | disclosed |
| US-4109008-A | SUBSTITUTED WITH AN AMIDINO AND A 1,3-DIMETHYL-2-OXO-BENZIMIDAZOL- 5-YL RADICAL | HEXACHIMIE (FR) | 1978-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250002499-A1 | Methyl 2-(Fluoromethyl)-5-Oxo-4-Phenyl-4,5,6,7-Tetrahydro-1h-Cyclopenta[B]Pyridine-3-Carboxylate And Methyl 2- (Fluoromethyl0-5-Oxo-4-Phenyl-1,4,5,7-Tetrahydrofuro[3,4-B]Purodine-3-Carboxylate As Cav1.2 Activators | RYR2, CACNA1D, CACNA1S | LMNA 1564/4885KMT2A 2016/4885MEN1 2934/4885 |
| US-12077536-B2 | BCL-2 inhibitors | BCL2, BCL2L1, BCL2L2 | LMNA 2914/4885KMT2A 2464/4885MEN1 3803/4885 |
| US-20250304594-A1 | METHYL (R)-2-(FLUOROMETHYL)-5-OXO-4-PHENYL-4,5,6,7-TETRAHYDRO-1H-CYCLOPENTA[B]PYRIDINE-3-CARBOXYLATE AND METHYL (R)-2-(FLUOROMETHYL)-5-OXO-4-PHENYL-1,4,5,7-TETRAHYDROFURO[3,4-B]PYRIDINE-3-CARBOXYLATE AS Cav1,2 ACTIVATORS | CACNA1D, CACNA1B, CACNA1S | LMNA 1615/4885KMT2A 1301/4885MEN1 2858/4885 |
| US-20240376104-A1 | Bcl-2 Inhibitors | BCL2, BCL2L1, BCL2L2 | LMNA 2914/4885KMT2A 2464/4885MEN1 3803/4885 |
| US-12365690-B2 | Methyl (R)-2-(fluoromethyl)-5-oxo-4-phenyl-4,5,6,7-tetrahydro-1H-cyclopenta[B]pyridine-3-carboxylate and methyl 2-(fluoromethyl)-5-oxo-4-phenyl-1,4,5,7-tetrahydrofuro[3,4-b]pyrodine-3-carboxylate as Cav1.2 activators | CACNA1D, CACNA1B, KCND2 | LMNA 1464/4885KMT2A 1096/4885MEN1 2539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.